The UKs NICE recommended semaglutide for adults with established CVD and BMI 27 kg/m in March 2025, opening NHS access to more than 1 million patients
In a blinded extension among participants with baseline BMI 35, weight loss continued through 104 weeks, reaching a mean of 30.3% [1][2]
Semaglutide treatment is suitable for a wide range of individuals, but its essential to determine if it aligns with your specific health needs
However, there are some differences between the two medicines that are fairly important to know about
The research, published on October 5, is the first large epidemiological study to focus on gastrointestinal issues in nondiabetic patients who use these medications for weight loss
The door of your refrigerator is the worst place to store peptides